Inventiva announced the completion of the final patient visit for its NATiV3 Phase 3 clinical trial for lanifibranor, a key milestone in its MASH drug development. Topline results are expected in Q4 2026, which will be a significant catalyst for the company and the broader MASH treatment market.
Inventiva has announced the completion of the final 72-week patient visit for its NATiV3 Phase 3 clinical trial for lanifibranor, a drug targeting MASH. This is a crucial operational milestone, indicating that all data collection for the primary endpoint is complete. The market impact is currently neutral as the actual topline results, expected in Q4 2026, will be the definitive catalyst. If results are favorable, it could lead to regulatory submission in H1 2027 and a potential U.S. launch in 2028, significantly boosting Inventiva's valuation. Conversely, unfavorable results would be a major setback. Traders should monitor for the Q4 2026 results as a high-impact event.